Elevated serum haptoglobin is associated with clinical outcome in triple-negative breast cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4541-4544

  Tabassum, Umaira ^a   Reddy, Obula ^a   Mukherjee, Geetashree ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

Hp; Prognosis; TNBC; Triple negative breast cancer

Indexed keywords

EID: 84874002023     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4541     Document Type: Article

References (21)

1. An JY, Fan ZM, Zhuang ZH, et al (2004). Proteomic analysis of blood level of proteins before and after operation in patients with esophageal squamous cell carcinoma at high-incidencearea in Henan Province. World J Gastroenterol, 10, 3365-8.
2. Awadallah SM, Atoum MF (2004). Haptoglobin polymorphism in breast cancer patients form Jordan. Clin Chim Acta, 341, 17-21.
3. Bartel U, Elling D, Geserick (1985). Distribution of haptoglobin phenotypes in gynecologic tumors. Zentralbl Gynakol, 107, 1492-5.
4. Beckman G, Eklund A, Frohlander N, et al (1986). Haptoglobin groups and lung cancer. Hum Hered, 36, 258-60.
5. Benkmann HG, Hanssen HP, Ovenbeck R, et al (1987). Distribution of alpha-1-antitrypsin and haptoglobin phenotypes in bladder cancer patients. Hum Hered, 37, 290-3.
6. Carlsson MC, Cederfur C, Schaar V, et al (2011). Galectin-1-binding glycoforms of haptoglobin with altered intracellular trafficking, and increase in metastatic breast cancer patients. PLoS One, 6, e26560.
7. Curigliano G, Goldhirsch A (2011). The triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monogr, 43, 108-10.
8. Dunzendorfer U, Jung K, Ohlenschlager G, et al (1980). Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors. Eur Urol, 6, 232-6.
9. Epelbaum R, Shalitin C, Segal R, et al (1998). Haptoglobin-related protein as a serum marker in malignant lymphoma. Pathol Oncol Res, 4, 271-6.
10. Fornier M, Fumoleau P (2012). The paradox of triple negative breast cancer: novel approaches to treatment. Breast J, 18, 41-51.
11. Gast MC, van Tinteren H, Bontenbal M, et al (2008). Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. BMC Cancer, 8, 389.
12. Gluz O, Liedtke C, Gottschalk N, et al (2009). Triple-negative breast cancer-current status and future directions. Ann Oncol, 20, 1913-27.
13. Kaur H, Bhardwaj DN, Shrivastava PK, et al (1984). Serum protein polymorphisms in breast cancer. Acta Anthropogenet, 8, 189-97.
14. Kawai T (1995). Past, present and future of enzyme immunoassay. Nihon Rinsho, 53, 2101-6.
15. Keam B, Im SA, Lee KH, et al (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res, 13, R22.
16. Kumar DM, Thota B, Shinde SV, et al (2010). Proteomic identification of haptoglobin alpha2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J Proteome Res, 9, 5557-67.
17. Lee DS, Kim SH, Suh YJ, et al (2011). Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy. Jpn J Clin Oncol, 41, 854-66.
18. Mitchell RJ, Carzino R, Janardhana V (1988). Associations between the two serum proteins haptoglobin and transferrin and leukaemia. Hum Hered, 38, 144-50.
19. Sadrzadeh SM, Bozorgmehr J (2004). Haptoglobin phenotypes in health and disorders. Am J Clin Pathol, 121, S97-104.
20. Tsamantanis C, Delinassios JG, Kottaridis S, et al (1980). Haptoglobin types in breast carcinoma. Hum Hered, 30, 44-5.
21. Zhao C, Annamalai L, Guo C, et al (2007). Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia, 9, 1-7.